These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28419449)

  • 1. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
    McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
    Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
    Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
    J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
    Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
    Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
    Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
    Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
    Sims RP
    J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
    Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
    Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
    Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
    J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
    Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
    Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia.
    Tay CG; Lee VWM; Ong LC; Goh KJ; Ariffin H; Fong CY
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28139029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
    Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
    JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients.
    Renbarger JL; McCammack KC; Rouse CE; Hall SD
    Pediatr Blood Cancer; 2008 Apr; 50(4):769-71. PubMed ID: 18085684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of vincristine induced neurotoxicity in children with acute lymphoblastic leukemia and its correlation with nutritional deficiencies.
    Dudeja S; Gupta S; Sharma S; Jain A; Sharma S; Jain P; Aneja S; Chandra J
    Pediatr Hematol Oncol; 2019 Sep; 36(6):344-351. PubMed ID: 31514565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics.
    Archer NP; Perez-Andreu V; Scheurer ME; Rabin KR; Peckham-Gregory EC; Plon SE; Zabriskie RC; De Alarcon PA; Fernandez KS; Najera CR; Yang JJ; Antillon-Klussmann F; Lupo PJ
    Cancer; 2016 Dec; 122(23):3697-3704. PubMed ID: 27529658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
    Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
    Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
    Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population.
    Gutierrez-Camino A; Martin-Guerrero I; Lopez-Lopez E; Echebarria-Barona A; Zabalza I; Ruiz I; Guerra-Merino I; Garcia-Orad A
    Pharmacogenet Genomics; 2016 Feb; 26(2):100-2. PubMed ID: 26618658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia.
    Hjalgrim LL; Madsen HO; Melbye M; Jørgensen P; Christiansen M; Andersen MT; Pallisgaard N; Hokland P; Clausen N; Ryder LP; Schmiegelow K; Hjalgrim H
    Br J Cancer; 2002 Oct; 87(9):994-9. PubMed ID: 12434291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
    Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
    Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
    Sági JC; Egyed B; Kelemen A; Kutszegi N; Hegyi M; Gézsi A; Herlitschke MA; Rzepiel A; Fodor LE; Ottóffy G; Kovács GT; Erdélyi DJ; Szalai C; Semsei ÁF
    BMC Cancer; 2018 Jul; 18(1):704. PubMed ID: 29970035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.